CRBU Overview

Caribou Biosciences, Inc. is a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company engaged in developing transformative therapies for patients with devastating diseases. The Company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against disease. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T platform to offer broad access and rapid availability of treatments for patients with hematologic malignancies and autoimmune diseases. Its genome-editing platform, including its novel chRDNA technology, enables more precise genome editing of allogeneic cell therapies. It is advancing its pipeline of allogeneic CAR-T cell therapies with clinical development programs targeting the treatment of hematologic malignancies and autoimmune diseases.

Wall Street analysts forecast CRBU stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRBU is8.00 USD with a low forecast of 6.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Caribou Biosciences Inc revenue for the last quarter amounts to 3.94M USD, increased 89.74

Caribou Biosciences Inc. EPS for the last quarter amounts to -0.28 USD, decreased -28.21

Caribou Biosciences Inc (CRBU) has 97 emplpoyees as of March 11 2026.

Today CRBU has the market capitalization of 196.17M USD.